123 related articles for article (PubMed ID: 30367903)
1. Use of the permitted daily exposure (PDE) concept for contaminants of intravitreal (IVT) drugs in multipurpose manufacturing facilities.
Lovsin Barle E; Pfister T; Fux C; Röthlisberger D; Jere D; Mahler HC
Regul Toxicol Pharmacol; 2019 Feb; 101():29-34. PubMed ID: 30367903
[TBL] [Abstract][Full Text] [Related]
2. Determination and application of the permitted daily exposure (PDE) for topical ocular drugs in multipurpose manufacturing facilities.
Lovsin Barle E; Bizec JC; Glogovac M; Gromek K; Winkler GC
Pharm Dev Technol; 2018 Mar; 23(3):225-230. PubMed ID: 28361586
[TBL] [Abstract][Full Text] [Related]
3. Topical otic drugs in a multi-purpose manufacturing facility: a guide on determination and application of permitted daily exposure (PDE).
Wiesner L; Prause M; Lovsin Barle E
Pharm Dev Technol; 2018 Mar; 23(3):261-264. PubMed ID: 28535123
[TBL] [Abstract][Full Text] [Related]
4. Cleaning Validation: Complete Guide for Health - Based Approach in Chemical Cross - Contamination Risk Assessment.
Tanyous JN
PDA J Pharm Sci Technol; 2019; 73(2):204-210. PubMed ID: 30361288
[TBL] [Abstract][Full Text] [Related]
5. Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) - Evidence of a robust approach.
Sehner C; Bernier T; Blum K; Clemann N; Glogovac M; Hawkins WA; Kohan M; Linker F; Lovsin-Barle E; Osadolor O; Pfister T; Schulze E; Schwind M; Tuschl G; Wiesner L
Regul Toxicol Pharmacol; 2024 Jun; 150():105649. PubMed ID: 38782234
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development.
del Amo EM; Vellonen KS; Kidron H; Urtti A
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):215-26. PubMed ID: 25603198
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal injection technique and monitoring: updated guidelines of an expert panel.
Avery RL; Bakri SJ; Blumenkranz MS; Brucker AJ; Cunningham ET; DʼAmico DJ; Dugel PU; Flynn HW; Freund KB; Haller JA; Jumper JM; Liebmann JM; McCannel CA; Mieler WF; Ta CN; Williams GA
Retina; 2014 Dec; 34 Suppl 12():S1-S18. PubMed ID: 25489719
[TBL] [Abstract][Full Text] [Related]
8. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
9. Challenges in setting permitted daily exposure limits for pharmaceuticals: A review.
Ahuja V; Krishnappa M
Int J Risk Saf Med; 2022; 33(1):49-64. PubMed ID: 34924402
[TBL] [Abstract][Full Text] [Related]
10. Deriving harmonised permitted daily exposures (PDEs) for paracetamol (acetaminophen) CAS #: 103-90-2.
Gromek K; Hawkins W; Bernier T; Sehner C; Zeller E; Schwind M; Pfister T; Kohan M; Osadolor O; Glogovac M; Tuschl G; Dolan DG; Lovsin Barle E
Regul Toxicol Pharmacol; 2020 Aug; 115():104692. PubMed ID: 32522580
[TBL] [Abstract][Full Text] [Related]
11. Controlling cleaning agent residues in pharmaceutical manufacturing: A harmonized scientific strategy.
Araya S; Pfister T; Blum K; Clemann N; Faltermann S; Wiesner L; Hawkins W; van de Gevel I; Versyck K
Regul Toxicol Pharmacol; 2023 Aug; 142():105430. PubMed ID: 37308050
[TBL] [Abstract][Full Text] [Related]
12. Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs).
Bercu JP; Morinello EJ; Sehner C; Shipp BK; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S48-56. PubMed ID: 27233925
[TBL] [Abstract][Full Text] [Related]
13. A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.
Hayes EP; Jolly RA; Faria EC; Barle EL; Bercu JP; Molnar LR; Naumann BD; Olson MJ; Pecquet AM; Sandhu R; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S39-47. PubMed ID: 27267172
[TBL] [Abstract][Full Text] [Related]
14. PDE concept for controlling cleaning agent residues in pharmaceuticals- A critical analysis.
Araya S; Pfister T; Gromek K; Hawkins W; Thomsen ST; Clemann N; Faltermann S; Wiesner L
Regul Toxicol Pharmacol; 2022 Feb; 128():105095. PubMed ID: 34890761
[TBL] [Abstract][Full Text] [Related]
15. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
Daull P; Paterson CA; Kuppermann BD; Garrigue JS
J Ocul Pharmacol Ther; 2013 Mar; 29(2):258-69. PubMed ID: 23331052
[TBL] [Abstract][Full Text] [Related]
16. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
[TBL] [Abstract][Full Text] [Related]
17. Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit Studies.
Fuchs H; Igney F
J Ocul Pharmacol Ther; 2017 Mar; 33(2):115-122. PubMed ID: 28055308
[TBL] [Abstract][Full Text] [Related]
18. What to consider for a good quality PDE document?
Sehner C; Schwind M; Tuschl G; Lovsin Barle E
Pharm Dev Technol; 2019 Sep; 24(7):803-811. PubMed ID: 30865481
[TBL] [Abstract][Full Text] [Related]
19. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
[TBL] [Abstract][Full Text] [Related]
20. [Potential of liposomes for the intravitreal injection of therapeutic molecules].
Bochot A; Lajavardi L; Camelo S; Bourges JL; Behar-Cohen F; de Kozak Y; Fattal E
Ann Pharm Fr; 2011 Mar; 69(2):100-7. PubMed ID: 21440102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
